These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22522007)

  • 21. Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Blaser A; Palmer BD; Sutherland HS; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Thompson AM; Denny WA
    J Med Chem; 2012 Jan; 55(1):312-26. PubMed ID: 22148391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancing the Therapeutic Potential of Indoleamides for Tuberculosis.
    Lun S; Tasneen R; Chaira T; Stec J; Onajole OK; Yang TJ; Cooper CB; Mdluli K; Converse PJ; Nuermberger EL; Raj VS; Kozikowski A; Bishai WR
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.
    Palencia A; Li X; Bu W; Choi W; Ding CZ; Easom EE; Feng L; Hernandez V; Houston P; Liu L; Meewan M; Mohan M; Rock FL; Sexton H; Zhang S; Zhou Y; Wan B; Wang Y; Franzblau SG; Woolhiser L; Gruppo V; Lenaerts AJ; O'Malley T; Parish T; Cooper CB; Waters MG; Ma Z; Ioerger TR; Sacchettini JC; Rullas J; Angulo-Barturen I; Pérez-Herrán E; Mendoza A; Barros D; Cusack S; Plattner JJ; Alley MR
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6271-80. PubMed ID: 27503647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorine and chlorine substituted adamantyl-urea as molecular tools for inhibition of human soluble epoxide hydrolase with picomolar efficacy.
    Burmistrov VV; Morisseau C; Danilov DV; Gladkikh BP; D'yachenko VS; Zefirov NA; Zefirova ON; Butov GM; Hammock BD
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2274797. PubMed ID: 37975322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.
    Tsai HJ; Hwang SH; Morisseau C; Yang J; Jones PD; Kasagami T; Kim IH; Hammock BD
    Eur J Pharm Sci; 2010 Jun; 40(3):222-38. PubMed ID: 20359531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
    De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
    J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and antitubercular screening of [(2-chloroquinolin-3-yl)methyl] thiocarbamide derivatives.
    Kumar S; Upmanyu N; Afzal O; Bawa S
    Chem Biol Drug Des; 2014 Nov; 84(5):522-30. PubMed ID: 24750991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.
    Burmistrov V; Morisseau C; Harris TR; Butov G; Hammock BD
    Bioorg Chem; 2018 Feb; 76():510-527. PubMed ID: 29310082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, biological evaluation and 3D-QSAR study of hydrazide, semicarbazide and thiosemicarbazide derivatives of 4-(adamantan-1-yl)quinoline as anti-tuberculosis agents.
    Patel SR; Gangwal R; Sangamwar AT; Jain R
    Eur J Med Chem; 2014 Oct; 85():255-67. PubMed ID: 25089809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
    Morisseau C; Newman JW; Tsai HJ; Baecker PA; Hammock BD
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5439-44. PubMed ID: 16908134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.
    Liu JY; Tsai HJ; Morisseau C; Lango J; Hwang SH; Watanabe T; Kim IH; Hammock BD
    Biochem Pharmacol; 2015 Dec; 98(4):718-31. PubMed ID: 26494425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacteria and Protozoa: Identification of Lead Compounds against
    Stampolaki M; Malwal SR; Alvarez-Cabrera N; Gao Z; Moniruzzaman M; Babii SO; Naziris N; Rey-Cibati A; Valladares-Delgado M; Turcu AL; Baek KH; Phan TN; Lee H; Alcaraz M; Watson S; van der Watt M; Coertzen D; Efstathiou N; Chountoulesi M; Shoen CM; Papanastasiou IP; Brea J; Cynamon MH; Birkholtz LM; Kremer L; No JH; Vázquez S; Benaim G; Demetzos C; Zgurskaya HI; Dick T; Oldfield E; Kolocouris AD
    ACS Infect Dis; 2023 Feb; 9(2):342-364. PubMed ID: 36706233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second generation of primaquine ureas and bis-ureas as potential antimycobacterial agents.
    Pavić K; Rajić Z; Michnová H; Jampílek J; Perković I; Zorc B
    Mol Divers; 2019 Aug; 23(3):657-667. PubMed ID: 30523579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.
    Gruppo V; Johnson CM; Marietta KS; Scherman H; Zink EE; Crick DC; Adams LB; Orme IM; Lenaerts AJ
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1245-50. PubMed ID: 16569835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
    Kim IH; Heirtzler FR; Morisseau C; Nishi K; Tsai HJ; Hammock BD
    J Med Chem; 2005 May; 48(10):3621-9. PubMed ID: 15887969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1
    Korycka-Machała M; Viljoen A; Pawełczyk J; Borówka P; Dziadek B; Gobis K; Brzostek A; Kawka M; Blaise M; Strapagiel D; Kremer L; Dziadek J
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
    Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
    Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.